Sinovac Named to Zhongguancun's Top 20 Most Influential Brands

2008-12-22

Sinovac Named to Zhongguancun's Top 20 Most Influential Brands
Monday December 22, 8:00 am ET

BEIJING, Dec. 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, today announced that it was recognized as one of Zhongguancun's Top 20 Most Influential Brands.

2008 marks only the 30th anniversary of China's reform and market liberation program along with the 20th anniversary of the establishment of the Zhongguancun, a technology hub situated in Beijing that is often referred to as "China's Silicon Valley". The Beijing municipal government recognizes the importance of advancing the development of this technology district that consists of more than 800 companies that contribute approximately 18% of Beijing's GDP. This year, the Beijing municipal government conducted a comprehensive study of experiences and developments within the Zhongguancun district for the last 20 years and named twenty leading technology companies to be the "Top 20 Most Influential Brands". Sinovac and other leading technology companies such as Sina, Lenovo, Aigo, Sohu and New Oriental were the recipients of this prestigious recognition. The award ceremony was held by the Administrative Committee of the Zhongguancun Science Park and was entitled, "Haidian Tells the World - Celebration of the 30th Anniversary of Reform and Liberalization, Celebration of the 20th Anniversary of the Foundation of Zhongguancun Science Park".

Mr. Weidong Yin, Chairman, President and CEO of Sinovac Biotech Ltd., commented, "We are pleased to be named as one of the most influential brands within the Beijing's high technology development zone. This recognition is a testament to Sinovac's commitment to providing comprehensive marketing and sales programs that support our brand in China. In addition, our vaccine research and development capabilities have enabled us to successfully commercialize three vaccines and continue to cultivate our development pipeline."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com .

    For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel:   +86-10-8289-0088 x871
Fax:   +86-10-6296-6910
Email: info@sinovac.com
Investors/Media:
Stephanie Carrington/Janine McCargo
The Ruth Group
Tel:   +1-646-536-7017/7033
Email: scarrington@theruthgroup.com
jmccargo@theruthgroup.com

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com